Rare Immunology News

Advertisement

Spotlight On

CTLA-4 Haploinsufficiency

CTLA-4 haploinsufficiency is a genetic disorder caused by a mutation in one copy of the CTLA-4 gene, leading to reduced CTLA-4 protein production. This results in a range of immune dysregulation issues, including autoimmunity, lymphoproliferation, and immunodeficiency

Prevalence

2/100,000

150–400

US Estimated

200–600

Europe Estimated

Age of Onset

All ages

ICD-10

D89.8

Inheritance

Autosomal dominant

Autosomal recessive

Mitochondrial/Multigenic

X-linked dominant

X-linked recessive

5 Facts you should know

FACT

1

CTLA-4 haploinsufficiency leads to a breakdown in immune tolerance, causing lymphoproliferation and multiple autoimmune manifestations, including cytopenias and enteropathy

FACT

2

Not all individuals with CTLA-4 mutations develop symptoms; affected members of the same family may exhibit very different clinical presentations

FACT

3

These are frequent findings, often accompanied by recurrent infections due to impaired immune regulation

FACT

4

This CTLA-4-Ig fusion protein can help manage autoimmunity by mimicking the regulatory function of CTLA-4

FACT

5

Early molecular diagnosis enables timely immunologic monitoring, family screening, and potential disease-modifying interventions

CTLA-4 haploinsufficiency is also known as...

CTLA-4 haploinsufficiency is also known as:

  • CTLA-4 Deficiency

    CTLA-4 Insufficiency with Autoimmunity

  • Immune Dysregulation, Primary Immunodeficiency with Autoimmunity

What’s your Rare IQ?

Which therapeutic agent mimics the action of CTLA-4 in patients with CTLA-4 Haploinsufficiency?

 

Common signs and symptoms

Recurrent infections

Autoimmune diseases

Lymphoproliferation

Hypogammaglobulinemia

Interstitial lung disease

Neurological involvement

Current treatments

Immunoglobulin replacement therapy

IVIG or SCIG

Immunosuppressive therapy

corticosteroids, sirolimus

Targeted therapy with Abatacept

CTLA-4 fusion protein

Hematopoietic stem cell transplantation (HSCT)

in severe or progressive cases

Management of autoimmune and infectious complications